کارگاه‌های آموزشی مرکز اطلاعات علمی

مقاله نویسی علوم انسانی

اصول تنظیم قراردادها

آموزش مهارت های کاربردی در تدوین و چاپ مقاله
Prenatal Diagnosis of β-thalassemia in Twin Pregnanacies in Iran

Zahra Kainimoghaddam BSc1, Atefeh Valaei MSc1, Fatemeh Bayat BSc1, Maryam Taghavi Basmanj BSc1, Fatemeh Navabmoghaddam BSc1, Marjanalsadat Mortezaazadeh BSc1, Ladan Teimoori-Toolabi MD PhD1, Setareh Ahmad1 BSc1, Shaghayegh Sadegh BSc1, Alireza Kordafshari BSc1, Morteza Karimipoor MD PhD1, Sirous Zeinali PhD1,2

Abstract:
Objective: Prenatal diagnosis of β-thalassemia carrier couples has helped to prevent bearing affected children. Among 177 couples referred to our laboratory for prenatal diagnosis, 14 mothers had twin pregnancies.

Methods: By using direct and indirect methods, we determined their mutations and linkage analysis using polymorphic markers (restriction fragment length polymorphism [RFLP]).

Results: It was shown that in five families both fetuses were heterozygote carriers. In another five families, one fetus was normal and the other one was carrier. In two families, one fetus was affected and the other one was heterozygous carrier; in one case one fetus was affected and the other one was homozygote normal. In the last family both fetuses were homozygote normal. If all fetuses were fraternal then one would expect to see seven homozygote normal and the same number affected, and 14 carriers.

Conclusion: Our results indicated that at least in cases where both fetuses had identical genotypes, then they may be identical twins. Molecular testing indeed showed that in three cases the twins were identical.

Keywords: β-thalassemia, prenatal diagnosis, RFLP, twins


Introduction

The β-thalassemia syndrome is an inherited hemoglobin disorder characterized by reduced production of β-globin chain. The severe forms of β-thalassemia produce marked anemia starting a few months after birth and survival relies on regular blood transfusion and the lifelong use of drugs to prevent iron accumulation.

It is estimated that 3% of the world’s population are carrier of β-thalassemia trait.1 This disease is a serious public-health problem, particularly in Iran and other parts of Middle-East and Asia2 where the frequency of β-thalassemia is higher than other parts of the world. More than 25000 affected patients have been reported to live in Iran.3

Identification of β-thalassemia carriers is essential in order to reduce the risk of bearing a child affected with severe anemia. For this reason, accurate diagnosis of carriers and proper genetic counseling is highly required. β-thalassemia carriers can initially be identified by measuring the mean corpuscular volume (MCV) and the mean corpusular hemoglobin (MCH) combined with HbA2 level. Premartial National Screening Program for Thalassemia Prevention was implemented in 1997.4 Prenatal diagnosis (PND) of β-thalassemia was established in Iran as early as 1994.5

PND for genetic disorders causing problems to the affected child, like β-thalassemia, DMD, etc., was legalized by the Iranian Parliament in 2005. Introduction of PND, in Iran, has lowered the birth rate of children affected with this disease dramatically.6 PND has its complications including identification of molecular defects, coinheritance of α- and β-thalassemia, sample mix-up, etc. Twin pregnancy is another problem since the fetal position may be confused or fraternal twins may have dissimilar genotypes, etc. In the present study, PND was performed for 14 couples with twin pregnancies among 177 families who had been at risk for β-thalassemia.

Patients and Methods

Fourteen twin pregnancies which were at risk of bearing fetuses affected with β-thalassemia were admitted to our PND center. The carrier status of β-thalassemia, in these couples, was assessed by hematologic indices (Table 1). Blood samples were collected in EDTA-containing tubes and DNAs were extracted by using salt-ing out method.6 Chorionic villi sampling (CVS) was obtained at the age of 10–12 weeks of gestation by the specialist. Chorionic villi (CV) were cleaned from blood clots and possible maternal decidua under microscope. DNA was extracted from CV using DNA Tissue Extraction, DNA Isolation Kit (Roche, Germany). β-globin gene mutations were analyzed using ARMSPCR,7 in parallel with RFLP/PCR analysis. Haplotype detection was performed by analyzing at least four restriction sites in the β-globin gene cluster mainly HinfI/3’ψβ, AvaII/β, HinfI/β, and Rsal/β. For RFLP analysis, parental DNAs were tested and linkages were obtained using their CBC and HbA2 results and if needed, parental mutations were obtained as above. Maternal contamination of fetal DNA was ruled out by using PCR analysis of several VNTRs.8 These markers include apolipoprotein β-gene (APOB),8 phenyl-
ketonuria (PKU), and DIS80 abbreviated as (PKU, APOB, and DIS80).

**Results**

Among β-thalassemia carrier couples who had been referred to our center for PND, 14 cases were twins. Eight of these couples were not relatives and the remaining were cousins. Family information is summarized in Table 2. Their relevant hematologic parameters are also included in Table 1. Polymorphic markers on β-globin gene cluster, were used routinely along with mutation analysis, to increase the accuracy of PND. In all cases, ARMS and RFLP results confirmed each other. When the results of mutation and RFLP marker in the fetus and mother were similar, VNTR markers were used to rule out maternal contamination. In all CV samples, fetal positions were marked on the tubes as right, left, anterior, posterior, upper, or lower. Fetal positions were carefully noticed and written down in reports.

Our results showed that in five families both fetuses were heterozygote carrier, while in five others one of the twins was normal and the other was heterozygote. In two families, one fetus was affected with β-thalassemia and the other onewas heterozygous, while in those two families one fetus was affected and the other one was heterozygous; in the last family both fetuses were homozygote normal. No maternal contamination was observed. No fetal loss was seen either. The affected fetuses were aborted after receiving permission from the Iranian Legal Medicine Organization by the specialist.

**Discussion**

PND is the best way for preventing birth of children affected with β-thalassemia. In Iran, premarital screening has become in effect since 1997. The program involves genetic counseling to inform individuals or couples at risk of carrying β-globin gene mutation.

Twin pregnancy is at higher risk of bearing a child with β-thalassemia since in each pregnancy the risk usually doubles. The problem becomes severe when one fetus is normal (homozygote or heterozygote) and the other one affected. Therefore, PND must be performed more accurately than singleton pregnancies. The positions of fetuses must be determined accurately by specialist and should be dealt with throughout the molecular tests. Marking the position of each fetus, in a twin pregnancy, is the most important part of the PND when fetal sampling is carried out, especially when one of them may be affected.

All of the fetuses were clearly genotyped and affected fetuses were aborted, while normal ones were unharmed (pregnancies were continued).
**Conclusion**

It is suggested to study more cases to see if the probability of 25%–50%–25% (major-minor-normal) is applicable in larger population of those fraternal twins or not. Also, it should be noted that for abortion of the affected fetus (affected with major thalassemia), more precise diagnosis and more caution in abortion should be applied.

**Acknowledgment**

*This study was supported by Pasteur Institute of Iran. We would like to thank Dr. Akhlaghpour for chorionic samplings, and Dr. Behdani and other colleagues at the Molecular Medicine Department for their help and assistance.*

**References**

کارگاه‌های آموزشی مرکز اطلاعات علمی

مقاله نویسی علوم انسانی

اصول تنظیم قراردادها

آموزش مهارت های کاربردی در تدوین و چاپ مقاله